These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 34998838)

  • 1. Lipid-based nanoparticulate delivery systems for HER2-positive breast cancer immunotherapy.
    Behravan N; Zahedipour F; Jaafari MR; Johnston TP; Sahebkar A
    Life Sci; 2022 Feb; 291():120294. PubMed ID: 34998838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functionalized immunostimulating complexes with protein A via lipid vinyl sulfones to deliver cancer drugs to trastuzumab-resistant HER2-overexpressing breast cancer cells.
    Rodríguez-Serrano F; Mut-Salud N; Cruz-Bustos T; Gomez-Samblas M; Carrasco E; Garrido JM; López-Jaramillo FJ; Santoyo-Gonzalez F; Osuna A
    Int J Nanomedicine; 2016; 11():4777-4785. PubMed ID: 27698563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polymer-lipid hybrid anti-HER2 nanoparticles for targeted salinomycin delivery to HER2-positive breast cancer stem cells and cancer cells.
    Li J; Xu W; Yuan X; Chen H; Song H; Wang B; Han J
    Int J Nanomedicine; 2017; 12():6909-6921. PubMed ID: 29075110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nano-pharmaceutical formulations for targeted drug delivery against HER2 in breast cancer.
    Sadat SM; Saeidnia S; Nazarali AJ; Haddadi A
    Curr Cancer Drug Targets; 2015; 15(1):71-86. PubMed ID: 25564255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A systematic review of dual targeting in HER2-positive breast cancer.
    Kümler I; Tuxen MK; Nielsen DL
    Cancer Treat Rev; 2014 Mar; 40(2):259-70. PubMed ID: 24080156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sticky Patches on Lipid Nanoparticles Enable the Selective Targeting and Killing of Untargetable Cancer Cells.
    Sempkowski M; Zhu C; Menzenski MZ; Kevrekidis IG; Bruchertseifer F; Morgenstern A; Sofou S
    Langmuir; 2016 Aug; 32(33):8329-38. PubMed ID: 27468779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cleavage of the extracellular domain of junctional adhesion molecule-A is associated with resistance to anti-HER2 therapies in breast cancer settings.
    Leech AO; Vellanki SH; Rutherford EJ; Keogh A; Jahns H; Hudson L; O'Donovan N; Sabri S; Abdulkarim B; Sheehan KM; Kay EW; Young LS; Hill ADK; Smith YE; Hopkins AM
    Breast Cancer Res; 2018 Nov; 20(1):140. PubMed ID: 30458861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progression and treatment of HER2-positive breast cancer.
    Davoli A; Hocevar BA; Brown TL
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multifunctional hybrid nanoparticles as magnetic delivery systems for siRNA targeting the HER2 gene in breast cancer cells.
    Cristofolini T; Dalmina M; Sierra JA; Silva AH; Pasa AA; Pittella F; Creczynski-Pasa TB
    Mater Sci Eng C Mater Biol Appl; 2020 Apr; 109():110555. PubMed ID: 32228895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent progress in immunotherapy of breast cancer targeting the human epidermal growth factor receptor 2 (HER2).
    Seyedmirzaei H; Keshavarz-Fathi M; Razi S; Gity M; Rezaei N
    J Oncol Pharm Pract; 2021 Jul; 27(5):1235-1244. PubMed ID: 33530866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Surface-tailored anti-HER2/neu-solid lipid nanoparticles for site-specific targeting MCF-7 and BT-474 breast cancer cells.
    Souto EB; Doktorovova S; Campos JR; Martins-Lopes P; Silva AM
    Eur J Pharm Sci; 2019 Feb; 128():27-35. PubMed ID: 30472221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and Evaluation of Tri-Functional Immunoliposomes for the Treatment of HER2 Positive Breast Cancer.
    Vaidya T; Straubinger RM; Ait-Oudhia S
    Pharm Res; 2018 Mar; 35(5):95. PubMed ID: 29536232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Copolymer micelles function as pH-responsive nanocarriers to enhance the cytotoxicity of a HER2 aptamer in HER2-positive breast cancer cells.
    Shen Y; Zhang J; Hao W; Wang T; Liu J; Xie Y; Xu S; Liu H
    Int J Nanomedicine; 2018; 13():537-553. PubMed ID: 29416334
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neural stem cells as a novel platform for tumor-specific delivery of therapeutic antibodies.
    Frank RT; Edmiston M; Kendall SE; Najbauer J; Cheung CW; Kassa T; Metz MZ; Kim SU; Glackin CA; Wu AM; Yazaki PJ; Aboody KS
    PLoS One; 2009 Dec; 4(12):e8314. PubMed ID: 20016813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What therapies are on the horizon for HER2 positive breast cancer?
    Viale G; Morganti S; Ferraro E; Zagami P; Marra A; Curigliano G
    Expert Rev Anticancer Ther; 2019 Sep; 19(9):811-822. PubMed ID: 31448640
    [No Abstract]   [Full Text] [Related]  

  • 16. Specific targeting of HER2 overexpressing breast cancer cells with doxorubicin-loaded trastuzumab-modified human serum albumin nanoparticles.
    Anhorn MG; Wagner S; Kreuter J; Langer K; von Briesen H
    Bioconjug Chem; 2008 Dec; 19(12):2321-31. PubMed ID: 18937508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Promises of Lipid-based Drug Delivery Systems in the Management of Breast Cancer.
    Thotakura N; Gupta MM; Rajawat JS; Raza K
    Curr Pharm Des; 2021; 27(45):4568-4577. PubMed ID: 34323182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Docetaxel immunonanocarriers as targeted delivery systems for HER 2-positive tumor cells: preparation, characterization, and cytotoxicity studies.
    Koopaei MN; Dinarvand R; Amini M; Rabbani H; Emami S; Ostad SN; Atyabi F
    Int J Nanomedicine; 2011; 6():1903-12. PubMed ID: 21931485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hitting multiple targets in HER2-positive breast cancer: proof of principle or therapeutic opportunity?
    Geuna E; Milani A; Redana S; Rossi V; Valabrega G; Aglietta M; Montemurro F
    Expert Opin Pharmacother; 2011 Mar; 12(4):549-65. PubMed ID: 21208143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced Human Epidermal Growth Factor Receptor 2 Degradation in Breast Cancer Cells by Lysosome-Targeting Gold Nanoconstructs.
    Lee H; Dam DH; Ha JW; Yue J; Odom TW
    ACS Nano; 2015 Oct; 9(10):9859-67. PubMed ID: 26335372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.